Research programme: microtubule associated protein tau modulators - PTC Therapeutics
Alternative Names: MAP-Tau - PTC TherapeuticsLatest Information Update: 11 Dec 2021
At a glance
- Originator PTC Therapeutics
- Class Neuroprotectants; Small molecules
- Mechanism of Action RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Neurodegenerative disorders
Most Recent Events
- 11 Dec 2021 Research programme: neurodegenerative disorders therapeutics - PTC Therapeutics is available for licensing as of 11 Dec 2021. https://www.ptcbio.com/our-science/expertise/alternative-splicing-programs/
- 01 Dec 2021 Early research in Neurodegenerative disorders in USA (PO) before December 2021 (PTC Therapeutics pipeline, December 2021)